Immunoprecise Antibodies Ltd (IPA)
ImmunoPrecise - ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using itsLENSai™ Platform Powered by Patented HYFT®Technology
ImmunoPrecise - ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using itsLENSai™ Platform Powered by Patented HYFT®Technology
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Energous Introduces Battery-Free e-Sense Tag, Establishing First End-to-End Wireless Power Platform for the Ambient IoT
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
The U.S. Food and Drug Administration Completes Review ofCibus’ Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
Bruker - Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands
Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development
Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
Tilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema